What Do We Know About Hypertrophic Cardiomyopathy in Poland in the Period 2016–2021 Based on Data From the Public Health System?

TL;DR

This study analyzed HCM trends in Poland from 2016–2021, showing declining new diagnoses but rising prevalence and mortality.

Contribution

The study provides the first comprehensive national analysis of HCM epidemiology and healthcare pathways in Poland.

Findings

Annual HCM incidence in Poland decreased from 3.89/100,000 in 2016 to 2.11/100,000 in 2021.

HCM prevalence increased from 34.53/100,000 in 2016 to 36.23/100,000 in 2021, indicating improved patient survival.

Annual mortality rose from 2.14/100,000 in 2016 to 2.67/100,000 in 2021, with highest rates in older adults.

Abstract

The aim of the study was to comprehensively characterize the population of hypertrophic cardiomyopathy (HCM) patients in Poland in 2016–2021, including the analysis of annual incidence, prevalence, comorbidities, and therapeutic paths.

A population-based cross-sectional study was conducted using data from the Polish National Health Fund database. The analysis included a registered annual incidence and prevalence rates, mortality, prognosis, and data on patients pathways in the healthcare system.

In 2016, the registered annual incidence of HCM diagnosis in Poland was 1,494 cases (3.89/100,000), decreasing to 808 cases (2.11/100,000) in 2021. Despite the decline in new diagnoses, the registered prevalence of HCM increased from 13,271 cases (34.53/100,000) in 2016 to 13,880 cases (36.23/100,000) in 2021, indicating improved patient survival. Annual mortality rose from 824 deaths (2.14/100,000) in 2016 to 1,022 deaths (2.67/100,000) in 2021, with the highest mortality observed in older adults (60+ years).

The study highlights significant underdiagnosis of HCM in Poland. Mortality in HCM population remains high, underscoring the need for improvement in earlier detection and comprehensive care strategies in Polish healthcare system.

Figures